http://rdf.ncbi.nlm.nih.gov/pubchem/patent/UA-134706-U
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B10-00 |
| filingDate | 2019-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | UA-134706-U |
| titleOfInvention | METHOD OF FORECASTING DEVELOPMENT OF PRIMARY RESISTANCE TO IMATINIBE THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA |
| abstract | A method for predicting the development of primary resistance to imatinib therapy in patients with chronic myeloid leukemia involves the analysis of the expression level of the chimeric BCR / ABL1 gene by quantitative reverse transcriptase polymerase chain reaction with real-time detection after 3 months and from the beginning of therapy. When exceeding the calculated critical threshold expression level of the chimeric BCR / ABL1 gene above 8.55%, predict a high probability of the development of primary resistance (adverse disease) for 12 months. imatinib therapy, and in the presence of expression level of the chimeric BCR / ABL1 gene (8.55%, predict low probability of developing primary resistance (favorable disease course) in patients with CML for 12 months of imatinib therapy. |
| priorityDate | 2019-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.